3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
16
Stage I Prostate Adenocarcinoma AJCC v7
1
Prostate Adenocarcinoma
1
Neoplasm Metastasis
1
Metastatic Hormone-Sensitive Prostate Cancer
1
Interventions
Radiosurgery
4
Magnetic Resonance Spectroscopy
4
luprolide acetate gel depot
3
enzalutamide
3
Radiotherapy
3
Radiation
3
Leuprolide
3
Goserelin
3
relugolix
2
gallium 68 PSMA-11
2
bicalutamide
2
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
2
Triptorelin Pamoate
2
Specimen Handling
2
Biopsy
2
radium Ra 223 dichloride
1
niraparib
1
histrelin
1
fluciclovine F-18
1
flibanserin
1
entinostat
1
darolutamide
1
atezolizumab
1
apalutamide
1
abiraterone
1
X-Rays
1
Watchful Waiting
1
Salicylic Acid
1
Receptors, Bombesin
1
Radium-223
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Prostate Adenocarcinoma
×
PROSTVAC
×
Clear all
NCT04020094
2021-09-22
AtezoVax
University of Utah
Phase 2
Withdrawn